SUPERNUS PHARMACEUTICALS, INC. Repayments of Secured Debt
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Repayments of Secured Debt of $24.34 million for the 12-month period ending 2013-12-31, per its 10-K/A filed 2017-01-20.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfSecuredDebt · last filed 2017-01-20
- SUPERNUS PHARMACEUTICALS, INC. repayments of secured debt for the quarter ending 2013-12-31 was $0.00, a 100.00% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. repayments of secured debt for the quarter ending 2013-09-30 was $0.00, a 100.00% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. repayments of secured debt for the quarter ending 2013-06-30 was $19.60M, a 1369.27% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. repayments of secured debt for the quarter ending 2013-03-31 was $2.83M, a 548.05% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. repayments of secured debt for fiscal 2013 was $24.34M, a 259.32% increase from fiscal 2012.
- SUPERNUS PHARMACEUTICALS, INC. repayments of secured debt for fiscal 2012 was $6.78M.
| Period end | Repayments of Secured Debt 0 month | Repayments of Secured Debt 3 month | Repayments of Secured Debt 6 month | Repayments of Secured Debt 9 month | Repayments of Secured Debt 12 month |
|---|---|---|---|---|---|
| 2013-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2017-01-20 | $0.00 derived: sum of 2 quarters · filed 2017-01-20 | $19.60M derived: sum of 3 quarters · filed 2017-01-20 | $24.34M 10-K/A · filed 2017-01-20 | |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | $19.60M derived: sum of 2 quarters · filed 2014-11-12 | $24.34M 10-Q · filed 2014-11-12 | $25.19M derived: sum of 4 quarters · filed 2015-03-12 | |
| 2013-06-30 | $19.60M 10-Q · filed 2013-08-14 | $24.34M 10-Q · filed 2014-08-12 | $25.19M derived: sum of 3 quarters · filed 2015-03-12 | $27.44M derived: sum of 4 quarters · filed 2015-03-12 | |
| 2013-05-03 | $19.60M 10-Q · filed 2013-11-13 | ||||
| 2013-03-31 | $2.83M 10-Q · filed 2014-05-13 | $5.59M derived: sum of 2 quarters · filed 2015-03-12 | $7.84M derived: sum of 3 quarters · filed 2015-03-12 | $9.17M derived: sum of 4 quarters · filed 2015-03-12 | |
| 2012-12-31 | $2.76M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $5.00M derived: sum of 2 quarters · filed 2015-03-12 | $6.34M derived: sum of 3 quarters · filed 2015-03-12 | $6.78M 10-K · filed 2015-03-12 | |
| 2012-09-30 | $2.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-13 | $3.58M derived: sum of 2 quarters · filed 2013-11-13 | $4.02M 10-Q · filed 2013-11-13 | ||
| 2012-06-30 | $1.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-14 | $1.77M 10-Q · filed 2013-08-14 | |||
| 2012-03-31 | $437.00K 10-Q · filed 2013-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |